ÂÜÀòÂÒÂ×

Dixitkumar Patel has a diverse work experience in the field of research and quality assurance. Dixitkumar started their career in 2012 as a Research Associate at Alembic Pharmaceuticals Limited, where they conducted fundamental and applied research on drug analysis in various matrices. Dixitkumar also performed extraction and calibration activities in the bioanalytical laboratory.

In 2014, Patel joined Accutest Research Laboratories (I) Pvt. Ltd. as a Research Associate, where they continued their research on drug analysis in different matrices for clinical studies. Dixitkumar compiled records and prepared bioanalytical reports for study sample analysis.

In 2015, Patel worked at Cadila Pharmaceuticals Limited as a Research Associate, responsible for method development, validation, and study sample analysis for BA BE study analysis. Dixitkumar conducted analytical experiments and research using chromatography, mass spectrometry, and other techniques.

Since 2016, Patel has been working at Lambda Therapeutic Research. Initially, they served as a Senior Research Associate in the Bioanalytical department, conducting analytical experiments and research on drug analysis in various matrices for clinical studies. Dixitkumar also operated and maintained laboratory equipment and apparatus. Later, they moved to the Quality Assurance Department, where they conducted audits, reviewed reports and protocols, and handled documents related to vendor qualification.

Overall, Dixitkumar Patel has gained extensive experience in research, analysis, and quality assurance within the pharmaceutical industry.

Dixitkumar Patel began their education in 2007 at Shree Krishna Institute of Pharmacy College, where they pursued a Bachelor of Pharmacy degree in Pharmacy. Dixitkumar successfully completed their undergraduate studies in 2011. Following this, they enrolled at Gujarat Technological University (GTU) in 2021 for a Master of Pharmacy degree in Pharmaceutical Quality Assurance. Their postgraduate studies are expected to be completed in 2023.